April 18 (Reuters) - Nykode Therapeutics ASA NYKD.OL :
* NYKODE THERAPEUTICS ANNOUNCES POSITIVE FINAL RESULTS FROM
ITS
PHASE 2 TRIAL OF VB10.16 IN COMBINATION WITH PD-L1 INHIBITOR
ATEZOLIZUMAB IN ADVANCED CERVICAL CANCER
* NYKODE THERAPEUTICS ASA - VB10.16 WAS SAFE AND WELL
TOLERATED IN
COMBINATION WITH ATEZOLIZUMAB
* NYKODE THERAPEUTICS- PLANS TO INITIATE POTENTIALLY
REGISTRATIONAL TRIAL IN PD-L1+ PATIENTS WITH HPV16-POSITIVE
ADVANCED CERVICAL CANCER IN U.S. IN 4Q
* NYKODE THERAPEUTICS:RESULTS SHOWED MEDIAN OVERALL SURVIVAL
GREATER THAN 25 MONTHS, 6.3 MONTHS MEDIAN PROGRESSION FREE
SURVIVAL IN PD-L1+ PATIENTS
Source text for Eikon: ID:nGNX89nlYw
Further company coverage: NYKD.OL
((Reuters.Briefs@thomsonreuters.com;))